Voltage-Gated Na Channels in Alzheimer's Disease: Physiological Roles and Therapeutic Potential

Overview

Journal Life (Basel)

Specialty Biology

Date 2023 Aug 26

PMID 37629512

Authors

Timothy J Baumgartner

Zahra Haghighijoo

Nana A Goode

Nolan M Dvorak

Parsa Arman

Fernanda Laezza

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and is classically characterized by two major histopathological abnormalities: extracellular plaques composed of amyloid beta (Aβ) and intracellular hyperphosphorylated tau. Due to the progressive nature of the disease, it is of the utmost importance to develop disease-modifying therapeutics that tackle AD pathology in its early stages. Attenuation of hippocampal hyperactivity, one of the earliest neuronal abnormalities observed in AD brains, has emerged as a promising strategy to ameliorate cognitive deficits and abate the spread of neurotoxic species. This aberrant hyperactivity has been attributed in part to the dysfunction of voltage-gated Na (Nav) channels, which are central mediators of neuronal excitability. Therefore, targeting Nav channels is a promising strategy for developing disease-modifying therapeutics that can correct aberrant neuronal phenotypes in early-stage AD. This review will explore the role of Nav channels in neuronal function, their connections to AD pathology, and their potential as therapeutic targets.

References

Bhaskar K, Konerth M, Kokiko-Cochran O, Cardona A, Ransohoff R, Lamb B . Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010; 68(1):19-31. PMC: 2950825. DOI: 10.1016/j.neuron.2010.08.023. View

Shavkunov A, Wildburger N, Nenov M, James T, Buzhdygan T, Panova-Elektronova N . The fibroblast growth factor 14·voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3). J Biol Chem. 2013; 288(27):19370-85. PMC: 3707642. DOI: 10.1074/jbc.M112.445924. View

Di Re J, Wadsworth P, Laezza F . Intracellular Fibroblast Growth Factor 14: Emerging Risk Factor for Brain Disorders. Front Cell Neurosci. 2017; 11:103. PMC: 5396478. DOI: 10.3389/fncel.2017.00103. View

Bolshakov V, Carboni L, Cobb M, Siegelbaum S, Belardetti F . Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat Neurosci. 2000; 3(11):1107-12. DOI: 10.1038/80624. View

L Pablo J, Pitt G . Fibroblast Growth Factor Homologous Factors: New Roles in Neuronal Health and Disease. Neuroscientist. 2014; 22(1):19-25. PMC: 4555190. DOI: 10.1177/1073858414562217. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Kumar M, Bansal N . Implications of Phosphoinositide 3-Kinase-Akt (PI3K-Akt) Pathway in the Pathogenesis of Alzheimer's Disease. Mol Neurobiol. 2021; 59(1):354-385. DOI: 10.1007/s12035-021-02611-7. View

Martinez-Losa M, Tracy T, Ma K, Verret L, Clemente-Perez A, Khan A . Nav1.1-Overexpressing Interneuron Transplants Restore Brain Rhythms and Cognition in a Mouse Model of Alzheimer's Disease. Neuron. 2018; 98(1):75-89.e5. PMC: 5886814. DOI: 10.1016/j.neuron.2018.02.029. View

Kaplan M, Cho M, Ullian E, Isom L, Levinson S, Barres B . Differential control of clustering of the sodium channels Na(v)1.2 and Na(v)1.6 at developing CNS nodes of Ranvier. Neuron. 2001; 30(1):105-19. DOI: 10.1016/s0896-6273(01)00266-5. View

10.

Rossor M, Garrett N, Johnson A, Mountjoy C, Roth M, Iversen L . A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain. 1982; 105(Pt 2):313-30. DOI: 10.1093/brain/105.2.313. View

11.

Klitgaard H . Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia. 2001; 42 Suppl 4:13-8. View

12.

Catterall W . Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy. Neurochem Res. 2017; 42(9):2495-2504. PMC: 5693772. DOI: 10.1007/s11064-017-2314-9. View

13.

Hu W, Tian C, Li T, Yang M, Hou H, Shu Y . Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nat Neurosci. 2009; 12(8):996-1002. DOI: 10.1038/nn.2359. View

14.

Roy S, Grum-Tokars V, Schavocky J, Saeed F, Staniszewski A, Teich A . Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015; 6(4):666-80. PMC: 4404319. DOI: 10.1021/acschemneuro.5b00002. View

15.

Ferguson B, Gao W . PV Interneurons: Critical Regulators of E/I Balance for Prefrontal Cortex-Dependent Behavior and Psychiatric Disorders. Front Neural Circuits. 2018; 12:37. PMC: 5964203. DOI: 10.3389/fncir.2018.00037. View

16.

Mackenzie R, Elliott B . Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014; 7:55-64. PMC: 3928478. DOI: 10.2147/DMSO.S48260. View

17.

Targa Dias Anastacio H, Matosin N, Ooi L . Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype?. Transl Psychiatry. 2022; 12(1):257. PMC: 9217953. DOI: 10.1038/s41398-022-02024-7. View

18.

Wadsworth P, Singh A, Nguyen N, Dvorak N, Tapia C, Russell W . JAK2 regulates Nav1.6 channel function via FGF14 phosphorylation. Biochim Biophys Acta Mol Cell Res. 2020; 1867(10):118786. PMC: 7984254. DOI: 10.1016/j.bbamcr.2020.118786. View

19.

Vico Varela E, Etter G, Williams S . Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. Neurobiol Dis. 2019; 127:605-615. DOI: 10.1016/j.nbd.2019.04.010. View

20.

Chang J, Parra-Bueno P, Laviv T, Szatmari E, Lee S, Yasuda R . CaMKII Autophosphorylation Is Necessary for Optimal Integration of Ca Signals during LTP Induction, but Not Maintenance. Neuron. 2017; 94(4):800-808.e4. PMC: 5573161. DOI: 10.1016/j.neuron.2017.04.041. View